The CYP2C9 enzyme breaks down compounds including steroid hormones and fatty acids. It also plays a major role in breaking down the drug warfarin, and helps metabolize other drugs such as ibuprofen. This shows CYP2C9 has both drug-metabolizing and endogenous metabolic roles in the human body.

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in **drug metabolism and synthesis of cholesterol, steroids and other lipids**. This protein localizes to the endoplasmic reticulum but its specific substrate has not yet been determined.

The human CYP2C subfamily appears to principally metabolize a number of clinically used drugs. Four members of this subfamily have been identified in humans: CYP2C8, CYP2C9, CYP2C18, and CYP2C19. CYP2C9 is important in the metabolism of therapeutically used drugs including warfarin and several nonsteroidal anti-inflammatory drugs.

CYP2C9 is one of the most abundant CYP enzymes in the human liver. It metabolizes more than 100 therapeutic drugs, and it also plays a role in the metabolism of several endogenous compounds such as steroids, melatonin, retinoids, and arachidonic acid.

Accumulating evidence indicates that CYP2C9 ranks amongst the most important drug-metabolizing enzymes in humans. There is also strong evidence supporting the involvement of CYP2C9 in the metabolism of multiple drugs, including tolbutamide, phenytoin, flurbiprofen, ibuprofen, and Δ9-THC.

Human CYP2C9 is one of the most abundant drug metabolizing cytochrome P450 (CYP) enzymes, being expressed in the liver at protein level similar to CYP3A4. CYP2C9 is involved in the metabolism of approximately 15–20% of clinically used drugs, such as anticoagulants (S-acenocoumarol, S-warfarin), antiepileptics (phenytoin, valproate), non-steroid anti-inflammatory drugs, oral antidiabetics, and angiotensin II receptor antagonists. Inhibition of CYP2C9 activity or transcriptional induction of CYP2C9 gene due to co-medication and other non-genetic factors can transiently switch into poor or extensive metabolizer phenotype.

CYP2C9 encodes a cytochrome P450 enzyme responsible for metabolizing up to 15% of small molecule drugs, and CYP2C9 variants can alter the effectiveness and safety of clinically used medications. Our data demonstrate that CYP2C9 plays a key role in drug metabolism and that genetic variation in CYP2C9 can have substantial functional consequences for drug clearance.

CYP2C9 is a phase I drug-metabolizing cytochrome P450 (CYP450) enzyme isoform that plays a major role in the oxidation of both xenobiotic and endogenous compounds. CYP2C9 is primarily expressed in the liver, and the expression level is reported to be the second highest among CYP isoforms. It has been estimated that CYP2C9 is responsible for the metabolic clearance of up to 15–20% of all drugs undergoing phase I metabolism. Besides drugs, CYP2C9 participates in the metabolism of endogenous substrates, including arachidonic acid to biologically active epoxyeicosatrienoic acids that have roles in vascular tone, inflammation, and other physiological processes.

CYP2C9 is an enzyme that is responsible for breaking down several of the drugs commonly used today. Some medications, such as celecoxib, warfarin, and phenytoin, require CYP2C9 in order to be metabolized to forms that are not active and more easily eliminated from the body.

Human cytochrome P450 (CYP) enzymes, as membrane-bound hemoproteins, **play important roles in the detoxification of drugs, cellular metabolism, and homeostasis**. CYP enzymes catalyze the oxidative biotransformation of a vast number of endogenous and exogenous compounds, thereby contributing to **drug clearance and the regulation of physiological processes**.

CYP2C9 metabolizes more than 100 clinically used drugs including phenytoin, S-warfarin, tolbutamide, glipizide, diclofenac, and losartan with varying contributions. CYP2C9 is considered one of the most important CYPs, with substrate specificity typical of many new chemical entities. Polymorphisms in CYP2C9 have the potential to affect the clearance and clinical response of CYP2C9 substrate drugs with low therapeutic indices such as warfarin and certain antidiabetic drugs. Because CYP2C9 is involved in the metabolism of endogenous compounds, genetic variation may also influence the levels of bioactive lipids and other molecules that have physiological roles, although this is less well characterized than its impact on drug therapy.

Human cytochrome P450 2C9 (CYP2C9) accounts for approximately 20% of hepatic total CYP content and metabolizes approximately 15% of clinical drugs such as phenytoin, (S)-warfarin, tolbutamide, losartan and several NSAIDs. Over 90% of human drug oxidation can be attributed to CYP1A2 (4%), 2A6 (2%), 2C9 (10%), 2C19 (2%), 2E1 (2%), 2D6 (30%), and 3A4 (50%), highlighting the major contribution of CYP2C9 to human drug metabolism.

CYP2C18 encodes a cytochrome P450 monooxygenase that participates in drug metabolism and the synthesis of cholesterol, steroids, and other lipids. This directly supports a role in metabolism and broader physiological functions.

It plays a key role in drug metabolism and cholesterol homeostasis by producing 25-hydroxycholesterol and oxygenating fatty acids and monoterpenes such as limonene, alpha-terpineol, and gamma-terpineol. It is involved in the metabolism of several classes of drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants, antidiabetics, and angiotensin II receptor antagonists.

Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an **NADPH-dependent electron transport pathway**. It **oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics**.

Cytochrome P450 (CYP) enzymes in extrahepatic tissues often **play a dominant role in target tissue metabolic activation of xenobiotic compounds**. They may also **determine drug efficacy and influence the tissue burden of foreign chemicals or bioavailability of therapeutic agents**. Many CYPs are expressed in one or more of these organs, including **CYP2C9 and CYP2C18**, indicating their participation in xenobiotic metabolism in respiratory and gastrointestinal tissues.

There is increasing evidence that CYP2C9 is important in the oxidative metabolism of acetic acid, propionic acid, fenemate and oxicam NSAIDs. CYP2C9 thus contributes substantially to the clearance of these nonsteroidal anti-inflammatory drugs in humans, underlining its major role in human drug metabolism.

CYP2C9 is an enzyme that plays a crucial role in drug metabolism. It is mainly found in the liver, where it helps to break down drugs and other foreign substances that enter the body. CYP2C9 is a member of the cytochrome P450 family of enzymes, which are responsible for metabolizing a wide range of substances, including drugs, toxins, and hormones. While best known for its role in the clearance of anticoagulants, NSAIDs, and anticonvulsants, CYP2C9 also participates in the metabolism of some endogenous hormones and fatty acids, thereby contributing indirectly to physiological functions such as blood pressure regulation and inflammatory responses.

Cytochrome P450 2C18 is a protein that in humans is encoded by the CYP2C18 gene. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which **catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids**. CYP2C18 also possesses **epoxygenase activity**: it can attack various long-chain polyunsaturated fatty acids at their double bonds to form **epoxide products that act as signaling agents**. It metabolizes arachidonic acid to various **epoxyeicosatrienoic acids (EETs)** and other epoxides that have biological signaling roles.

Cytochrome P450 (CYP) enzymes are by far the most important players in **phase 1 drug metabolism**. CYP enzymes **catalyze heme-dependent substrate monooxygenation**, which typically enhances metabolite polarity and facilitates **elimination from the body**. Together, human CYP3A4 and CYP2D6 contribute to the metabolism of approximately 75% of all drugs in clinical use, and both enzymes are implicated in adverse drug interactions and drug resistance, illustrating how CYP-mediated metabolism directly affects **physiological handling of xenobiotics**.

CYP2C18 is discussed as a cytochrome P450 family member in the context of expression and function, with the topic overview indicating involvement in biochemical pathways relevant to metabolism. The page is a secondary topic summary rather than a primary study.

Cytochromes P450 2C, including **CYP2C9**, are among the major drug-metabolizing enzymes in humans. CYP2C9 **catalyzes the oxidative metabolism of numerous clinically important drugs**, such as warfarin, phenytoin, tolbutamide, and many nonsteroidal anti-inflammatory drugs. Genetic polymorphisms in CYP2C9 can lead to **altered drug clearance and variation in therapeutic response and toxicity**, demonstrating a direct impact on drug metabolism and associated physiological outcomes.

CYP2C9*3 was found to play an important role in the metabolism of meloxicam by reducing its enzymatic activity. Data show that the allele is associated with decreased clearance of meloxicam, demonstrating that CYP2C9 variants can alter metabolism of specific NSAID drugs in humans.

CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most important contributor from this subfamily to drug metabolism.

Human CYP2C subfamily enzymes such as **CYP2C9 and CYP2C19** are expressed in liver and extrahepatic tissues, where they contribute to **phase I metabolism of xenobiotics and endogenous compounds**. By oxidizing drugs and other chemicals, these enzymes influence **drug clearance, pharmacokinetics, and potential tissue-specific toxicity**, linking their enzymatic activity to broader **physiological functions** like detoxification and maintenance of chemical homeostasis.

CYP2C9 is one of the most important drug metabolizing enzymes and accounts for the metabolism of about 13%–17% of clinically used drugs, according to the article’s functional characterization background. This is a recent peer-reviewed secondary source supporting its central metabolic role.

Wikipedia summarizes that CYP2C9 is involved in the oxidation of xenobiotics, including drugs, and endogenous compounds, including fatty acids, and notes expression mainly in the liver, duodenum, and small intestine. This is low-authority background only.